Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.38 |
| ▸ | RXRB | P28702 | 12/20 | 0.38 |
| ▸ | RXRG | P48443 | 9/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17581149 | 0.87 | RIPK2 (0.38) | RXRARXRBRXRGPLAUTLR7 | |
| SCHEMBL31543572 | 0.82 | RXRA (0.36) | RXRARXRBRXRGPLAUTLR7 | |
| SCHEMBL1914478 | 0.81 | NQO2 (0.39) | RXRARXRBRXRGPPARGPPARD | |
| SCHEMBL28803013 | 0.81 | RXRA (0.39) | RXRARXRBRXRGL3MBTL1PPARG | |
| SCHEMBL28803019 | 0.79 | RXRA (0.43) | RXRARXRBRXRGPPARGPPARD | |
| SCHEMBL25659408 | 0.79 | TSHR (0.41) | TSHRPOLBL3MBTL1TLR7NUDT1 | |
| SCHEMBL25136401 | 0.79 | BCHE (0.38) | PLAUTSHRPOLBL3MBTL1 | |
| SCHEMBL6223037 | 0.79 | TSHR (0.38) | RXRAPLAUTSHRTLR7NUDT1 | |
| SCHEMBL917646 | 0.78 | TLR7 (0.35) | PLAUTSHRPOLBL3MBTL1TLR7 | |
| SCHEMBL8960380 | 0.78 | TSHR (0.36) | PLAUTSHRPOLBL3MBTL1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2024125451-A1 | PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024125464-A1 | TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| CN-117940433-A | Quinoline furan derivative and application thereof | 瑞石生物医药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023025298-A1 | QUINOLINOFURAN DERIVATIVE AND USE THEREOF | 瑞石生物医药有限公司 | 2023-03-02 | — | — | WO | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | RXRA 4447/4885RXRB 4414/4885RXRG 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.